MicroRNA 4492 (miR-4492)

MicroRNA 4492 (miR-4492) is a small, non-coding RNA molecule that regulates gene expression post-transcriptionally, primarily by binding to messenger RNAs and inhibiting their translation or promoting their degradation[1][4]. It is classified as a microRNA, part of the non-coding RNA family. miR-4492 plays significant roles in various biological processes such as cell proliferation, migration, invasion, apoptosis, and cell cycle control, largely through its regulatory activities on multiple target genes, including ROMO1, HLA-G, NKIRAS2, FOXK1, and UBE2C[1]. miR-4492 has been widely studied in the context of cancer, where it acts as either a tumor suppressor or, in certain situations, an oncogene. Its dysregulation has been observed in several malignancies, such as ovarian, bladder, breast, colorectal, osteosarcoma, glioblastoma, and hepatocellular carcinomas[1]. In cancer, miR-4492 may be sponged by specific long non-coding RNAs, affecting signaling pathways related to cell proliferation and migration. miR-4492 has potential as a diagnostic and prognostic biomarker, as its circulating levels in bodily fluids (like plasma) can predict response to therapies, e.g., transarterial chemoembolization in hepatocellular carcinoma[1][2]. Current data do not link miR-4492 to direct interactions with small molecule drugs or therapeutic agents, nor are specific mechanisms of drug action targeting this miRNA clinically established. However, it is considered a promising target for future RNA-based therapeutic approaches due to its role in malignancies and its measurable effects as a biomarker for diagnosis and monitoring of cancer therapy[1].

Other names

hsa-miR-4492MIR4492mir-4492